Literature DB >> 32269693

Endometrial polyp-like perivascular epithelioid cell neoplasm associated with TFE3 translocation: report of one case.

Yanting Hu1, Lixia Wang1, Hongqi Shi1, Bin Hu1.   

Abstract

This article reports the pathologic features and malignant biological behavior of a perivascular epithelioid cell neoplasm (PEComa) with the clinical manifestation being endometrial polyps. The case was cured with curettage in a local hospital one year ago. The postoperative diagnosis was "endometrial polyps". This time, due to "irregular bleeding", we carried out another curettage in our hospital. After the operation, 3 pieces of polyps were inspected with diameters of 0.3 cm, 0.5 cm and 0.6 cm, respectively. The tumor consisted of epithelioid cells with alveolar and nesting pattern and showed a diffuse strong expression of HMB45, Melan-A and TFE3. The patient then underwent a hysterectomy and the "polyps" were sent for pathological examination. The result showed that tumor cells infiltrated the deep muscle layer, close to the outer membrane, suggesting a malignant biologic behavior. TFE3-related PEComa is different from general PEComa. This neoplasm and Melanotic Xp11 renal carcinoma have similar clinicopathologic features, histology, immunity and molecular phenotypes, belonging to the same type of tumor. It has been suggested in the literature naming this neoplasm as 'Xp11 neoplasm with melanocytic differentiation' or 'melanotic Xp11 neoplasm'. Our case has expanded our understanding of PEComa characteristics and increased data for TFE3 translocation-related PEComa, reminding us to avoid misdiagnosis when PEComa manifests as small polyps. IJCEP
Copyright © 2020.

Entities:  

Keywords:  Endometrial polyp; TFE3 translocation; perivascular epithelioid cell neoplasm

Year:  2020        PMID: 32269693      PMCID: PMC7137019     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  18 in total

1.  First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor.

Authors:  Hannah Gondran; Estelle Thebaud; Anne Moreau; Marc Le Rhun; Yann Touchefeu; Nicolas Regenet; Nicolas Musquer
Journal:  Pancreatology       Date:  2019-05-18       Impact factor: 3.996

Review 2.  Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature.

Authors:  Andrew L Folpe; Thomas Mentzel; Hans-Anton Lehr; Cyril Fisher; Bonnie L Balzer; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2005-12       Impact factor: 6.394

3.  Perivascular epithelioid cell tumor of the cervix with malignant potential.

Authors:  Cai Zhang; Feibao Pan; Jian Qiao; Shufen Jiang; Ying Du; Chunquan Zhao
Journal:  Int J Gynaecol Obstet       Date:  2013-07-10       Impact factor: 3.561

4.  Malignant perivascular epithelioid cell neoplasm (PEComa) of the urinary bladder with TFE3 gene rearrangement: clinicopathologic, immunohistochemical, and molecular features.

Authors:  Sean R Williamson; Paula J Bunde; Rodolfo Montironi; Antonio Lopez-Beltran; Shaobo Zhang; Mingsheng Wang; Gregory T Maclennan; Liang Cheng
Journal:  Am J Surg Pathol       Date:  2013-10       Impact factor: 6.394

5.  Clear cell myomelanocytic tumor of the falciform ligament/ligamentum teres: a novel member of the perivascular epithelioid clear cell family of tumors with a predilection for children and young adults.

Authors:  A L Folpe; Z D Goodman; K G Ishak; A F Paulino; E M Taboada; S A Meehan; S W Weiss
Journal:  Am J Surg Pathol       Date:  2000-09       Impact factor: 6.394

6.  Role of Chemotherapy, VEGFR Inhibitors, and mTOR Inhibitors in Advanced Perivascular Epithelioid Cell Tumors (PEComas).

Authors:  Roberta Sanfilippo; Robin L Jones; Jean-Yves Blay; Axel Le Cesne; Salvatore Provenzano; Georgios Antoniou; Olivier Mir; Giovanni Fucà; Elena Fumagalli; Rossella Bertulli; Silvia Stacchiotti; Mehdi Brahmi; Federica Grosso; Armelle Dufresne; Nadia Hindi; Marta Sbaraglia; Alessandro Gronchi; Paola Collini; Angelo P Dei Tos; Paolo G Casali
Journal:  Clin Cancer Res       Date:  2019-06-19       Impact factor: 12.531

7.  TFE3 translocation-associated perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: morphology, immunophenotype, differential diagnosis.

Authors:  J Kenneth Schoolmeester; Linda N Dao; William R Sukov; Lu Wang; Kay J Park; Rajmohan Murali; Meera R Hameed; Robert A Soslow
Journal:  Am J Surg Pathol       Date:  2015-03       Impact factor: 6.394

8.  Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene fusion in a patient with advanced neuroblastoma.

Authors:  Mio Tanaka; Keisuke Kato; Kiyoshi Gomi; Masae Matsumoto; Hironori Kudo; Masato Shinkai; Youkatsu Ohama; Hisato Kigasawa; Yukichi Tanaka
Journal:  Am J Surg Pathol       Date:  2009-09       Impact factor: 6.394

9.  PEComa of the gastrointestinal tract: clinicopathologic study of 35 cases with evaluation of prognostic parameters.

Authors:  Leona A Doyle; Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2013-12       Impact factor: 6.394

10.  Malignant perivascular epithelioid cell tumor (PEComa) arising in the broad ligament.

Authors:  D Fink; D E Marsden; L Edwards; C Camaris; N F Hacker
Journal:  Int J Gynecol Cancer       Date:  2004 Sep-Oct       Impact factor: 3.437

View more
  2 in total

Review 1.  TFE3-associated perivascular epithelioid cell tumor with complete response to mTOR inhibitor therapy: report of first case and literature review.

Authors:  Roli Purwar; Kishan Soni; Mridula Shukla; Ashish Verma; Tarun Kumar; Manoj Pandey
Journal:  World J Surg Oncol       Date:  2022-03-01       Impact factor: 2.754

Review 2.  Laparoscopic radical nephroureterectomy in the oblique supine lithotomy integrative position for rare renal malignant perivascular epithelioid cell tumor with renal vein cancerous thrombosis: A case report and literature review.

Authors:  Canbin Lin; Shulin Liang; Yongxing Wang; Aidi Liang; Weiting Qin; Jiapeng Huang; Hao Meng; Hong Liu; Ming Chen; Lei Meng
Journal:  Medicine (Baltimore)       Date:  2022-09-23       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.